Cargando…
MicroRNA signature in classical Hodgkin lymphoma
Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large n...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032569/ https://www.ncbi.nlm.nih.gov/pubmed/33544339 http://dx.doi.org/10.1007/s13353-021-00614-7 |
_version_ | 1783676234227515392 |
---|---|
author | Paczkowska, Julia Giefing, Maciej |
author_facet | Paczkowska, Julia Giefing, Maciej |
author_sort | Paczkowska, Julia |
collection | PubMed |
description | Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large number of genetic and epigenetic alterations. Recently, microRNA profiling studies highlighted the importance of small non-coding RNA in cHL. This review summarizes available literature data and provides a detailed comparison of four studies where cHL cell lines and microdissected HRS cells were used. Several microRNAs were found to be consistently up- (let-7-f, mir-9, mir-21, mir-23a, mir-27a, mir-155, and mir-196a) or downregulated (mir-138 and mir-150) in cHL. These deregulated microRNAs are involved in the processes crucial for cHL pathogenesis, such as impaired B cell development (mir-9, mir-150, and mir-155), NFκB hyperactivation (mir-155 and mir-196a), and immune evasion (mir-138). Therefore, the deregulation of microRNA expression can be considered a complementary mechanism to genetic alterations promoting lymphomagenesis. Moreover, the expression of let-7f, mir-9 and mir-27a is specific for cHL and can serve as a biomarker to distinguish this lymphoma from other B cell lymphomas. However, additional in-depth and high throughput analysis of microRNA expression in HRS cells is necessary to decipher the complete picture of microRNA in cHL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13353-021-00614-7. |
format | Online Article Text |
id | pubmed-8032569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80325692021-04-27 MicroRNA signature in classical Hodgkin lymphoma Paczkowska, Julia Giefing, Maciej J Appl Genet Human Genetics • Mini-Review Classical Hodgkin lymphoma (cHL) is one of the most prevalent lymphomas with a unique cell composition compared to other lymphoma entities. Rare, malignant Hodgkin and Reed-Sternberg (HRS) cells embedded with an extensive but ineffective immune infiltration were previously characterized by a large number of genetic and epigenetic alterations. Recently, microRNA profiling studies highlighted the importance of small non-coding RNA in cHL. This review summarizes available literature data and provides a detailed comparison of four studies where cHL cell lines and microdissected HRS cells were used. Several microRNAs were found to be consistently up- (let-7-f, mir-9, mir-21, mir-23a, mir-27a, mir-155, and mir-196a) or downregulated (mir-138 and mir-150) in cHL. These deregulated microRNAs are involved in the processes crucial for cHL pathogenesis, such as impaired B cell development (mir-9, mir-150, and mir-155), NFκB hyperactivation (mir-155 and mir-196a), and immune evasion (mir-138). Therefore, the deregulation of microRNA expression can be considered a complementary mechanism to genetic alterations promoting lymphomagenesis. Moreover, the expression of let-7f, mir-9 and mir-27a is specific for cHL and can serve as a biomarker to distinguish this lymphoma from other B cell lymphomas. However, additional in-depth and high throughput analysis of microRNA expression in HRS cells is necessary to decipher the complete picture of microRNA in cHL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13353-021-00614-7. Springer Berlin Heidelberg 2021-02-05 2021 /pmc/articles/PMC8032569/ /pubmed/33544339 http://dx.doi.org/10.1007/s13353-021-00614-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Human Genetics • Mini-Review Paczkowska, Julia Giefing, Maciej MicroRNA signature in classical Hodgkin lymphoma |
title | MicroRNA signature in classical Hodgkin lymphoma |
title_full | MicroRNA signature in classical Hodgkin lymphoma |
title_fullStr | MicroRNA signature in classical Hodgkin lymphoma |
title_full_unstemmed | MicroRNA signature in classical Hodgkin lymphoma |
title_short | MicroRNA signature in classical Hodgkin lymphoma |
title_sort | microrna signature in classical hodgkin lymphoma |
topic | Human Genetics • Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032569/ https://www.ncbi.nlm.nih.gov/pubmed/33544339 http://dx.doi.org/10.1007/s13353-021-00614-7 |
work_keys_str_mv | AT paczkowskajulia micrornasignatureinclassicalhodgkinlymphoma AT giefingmaciej micrornasignatureinclassicalhodgkinlymphoma |